Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases
(IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease
(CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology,
natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its
function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing
pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be
promising therapeutic strategies for the future management of IBD and other human diseases.
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative
Rights & PermissionsPrintExport
Published on: 29 October, 2013
Page: [1444 - 1452]